Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 21, 2009British Journal of Clinical PharmacologyOpen Access

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV‐infected patients

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAwewura KwaraUniversity of FloridaMLMargaret LarteyUniversity of GhanaKSKwamena William Coleman SagoeUniversity of Ghana

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kwara et al. (2009) studied this question.

synapsesocial.com/papers/6a7a5bf0b2ad017e403224fchttps://doi.org/10.1111/j.1365-2125.2009.03368.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV2006 · 117 citations
  2. 2Pharmacokinetics of Efavirenz When Co‐administered With Rifampin in TB/HIV Co‐infected Patients: Pharmacogenetic Effect of<i>CYP2B6</i>Variation2008 · 52 citations
  3. 3Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy2006 · 81 citations
  4. 4Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV2006 · 887 citations
  5. 5Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin2005 · 84 citations